July 11, 2018

Chief clinical and compliance officer, Dr. Tom Doub and National Medical Director, Dr. Marc Calarco discuss the relevance and importance of groundbreaking technology, EarlySense.

“This decision was all about patient safety, and we’ve been very focused on reducing risks as patients go through detox,” said Tom Doub

“EarlySense adds another layer of safety for both patients and staff,” said Mark Calarco

To read the entire article please visit: Nashville Medical News Dr. Tom Doub Dr. Mark Calarco